| Literature DB >> 28286692 |
Junghwa Lee1, Eunseon Ahn1, Haydn T Kissick1, Rafi Ahmed1.
Abstract
T-cell exhaustion due to persistent antigen stimulation is a key feature of chronic viral infections and cancer. Programmed cell death-1 (PD-1) is a major regulator of T-cell exhaustion, and blocking the PD-1 pathway restores T-cell function and improves pathogen control and tumor eradication. Immunotherapy targeting the PD-1 inhibitory receptor pathway has demonstrated significant antitumor activity. Recently, antibodies blocking PD-1 have been approved for use in cancer patients. In this review, we summarize the role of the PD-1 pathway in chronic infection and cancer and the therapeutic potential of PD-1-directed immunotherapy in patients with chronic infection or cancer.Entities:
Keywords: T-cell exhaustion; cancer; chronic infection; immunotherapy; programmed cell death-1
Year: 2015 PMID: 28286692 PMCID: PMC5341794 DOI: 10.1615/ForumImmunDisTher.2015014188
Source DB: PubMed Journal: For Immunopathol Dis Therap ISSN: 2151-8017